Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2010 2
2011 1
2013 1
2014 1
2015 1
2016 2
2019 1
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Targeting p73 in cancer.
Maas AM, Bretz AC, Mack E, Stiewe T. Maas AM, et al. Among authors: bretz ac. Cancer Lett. 2013 May 28;332(2):229-36. doi: 10.1016/j.canlet.2011.07.030. Epub 2011 Aug 22. Cancer Lett. 2013. PMID: 21903324 Review.
CRISPR-Cas9-based target validation for p53-reactivating model compounds.
Wanzel M, Vischedyk JB, Gittler MP, Gremke N, Seiz JR, Hefter M, Noack M, Savai R, Mernberger M, Charles JP, Schneikert J, Bretz AC, Nist A, Stiewe T. Wanzel M, et al. Among authors: bretz ac. Nat Chem Biol. 2016 Jan;12(1):22-8. doi: 10.1038/nchembio.1965. Epub 2015 Nov 23. Nat Chem Biol. 2016. PMID: 26595461 Free PMC article.
A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
Tonigold M, Rossmann A, Meinold M, Bette M, Märken M, Henkenius K, Bretz AC, Giel G, Cai C, Rodepeter FR, Beneš V, Grénman R, Carey TE, Lage H, Stiewe T, Neubauer A, Werner JA, Brendel C, Mandic R. Tonigold M, et al. Among authors: bretz ac. J Cancer Res Clin Oncol. 2014 Oct;140(10):1689-704. doi: 10.1007/s00432-014-1727-y. Epub 2014 Jun 10. J Cancer Res Clin Oncol. 2014. PMID: 24913304